Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_4
2
33%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Other(2)

Detailed Status

Completed4
unknown2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 23 (50.0%)
Phase 42 (33.3%)
N/A1 (16.7%)

Trials by Status

completed467%
unknown233%

Recent Activity

0 active trials
Showing 5 of 6
unknownphase_4

Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease

NCT04952194
completedphase_2

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

NCT02764125
unknownnot_applicable

Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease

NCT02452606
completedphase_4

Study to Evaluate Initiation of Stalevo in Early Wearing-off

NCT00462007
completedphase_2

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

NCT01766258
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04952194Phase 4

Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease

Unknown
NCT02764125Phase 2

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

Completed
NCT02452606Not Applicable

Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease

Unknown
NCT00462007Phase 4

Study to Evaluate Initiation of Stalevo in Early Wearing-off

Completed
NCT01766258Phase 2

Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations

Completed
NCT00200447Phase 2

An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN)

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6